Adaptive biotech stock.

Shares of Adaptive Biotechnologies (ADPT-5.20%) soared when the biotech took steps to address the coronavirus pandemic and partnered with Amgen (AMGN 1.14%) and Microsoft (MSFT 0.02%) in the process.

Adaptive biotech stock. Things To Know About Adaptive biotech stock.

Jun 11, 2020 · Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has ... Adaptive Biotechnologies's earnings have been declining at an average annual rate of -27.9%, while the Life Sciences industry saw earnings growing at 20.7% annually. Revenues have been growing at an average rate of 24.4% per year.With the company starting 2023 with 8,725 employees, that’s an 11.5% workforce reduction. Story. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut ...On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter. 10 analysts are forecasting losses of $0.351 per share as opposed to losses of $0.430 per share in the ...Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ...

A biotech consultant is an adviser to executives and managers who direct and oversee operations within a biotechnology company. Biotech consultants provide guidance to these types of companies and support improvements and developments in efficiency, product efficacy and organizational processes. Consultants in biotechnology …

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter of 2023 …The IPO market started off blazing hot in 2021, but valuations and interest began to cool toward the end of the year. Still, we saw a record-breaking 100 listings, with more and more companies ...

Nov 9, 2023 · SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has ...From inception in 2012 through November, the Zacks Top 10 Stocks gained an impressive +962.5% versus the S&P 500’s +329.4%. Now our Director of Research is combing through 4,000 companies ...The latest closing stock price for Adaptive Biotechnologies as of October 31, 2023 is 4.44. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on January 22, 2021. The Adaptive Biotechnologies 52-week high stock price is 10.79, which is 143% above the current share price. The Adaptive Biotechnologies 52-week low stock ...In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock. Percentage Held by Insiders. Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders. Percentage Held by Institutions

The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price.

The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on …

Oct 19, 2023 · Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%. ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations 201-396-1687 [email protected]. ADAPTIVE MEDIA Erica Jones, Associate Corporate Communications Director 206-279-2423 [email protected]. Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share ...Adaptive Biotechnologies (NASDAQ: ADPT) is owned by 97.04% institutional shareholders, 59.51% Adaptive Biotechnologies insiders, and 0.00% retail investors. Viking Global Performance LLC is the largest individual Adaptive Biotechnologies shareholder, owning 30.99M shares representing 21.41% of the company.Sep 30, 2022 · 2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ... Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Earnings Date. Jan 29, 2024 - Feb 02, 2024. Forward Dividend & Yield. 8.52 (3.16%) Ex-Dividend Date. Nov 16, 2023. 1y Target Est. 277.83. Fair Value is the appropriate price for the shares of a ...HQ: 1165 Eastlake Ave E Seattle, WA 98109. Labs: 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102

As of March 31, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.83. Adaptive Biotechnologies Corp is up 4.87% from its previous closing price of $8.42. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.21 and $8.67. Currently, there are 143.06 million shares of Adaptive ...Information on stock, financials, earnings, subsidiaries, investors, and executives for Adaptive Biotechnologies. Use the PitchBook Platform to explore the ...16 biotech companies in Seattle. following are 16 biotech companies in Seattle: 1. Just – Evotec Biologics. Founded in: 2014. Size: 101-500 employees. Description: Just – Evotec Biologics specializes in developing high-quality and cost-efficient biotherapeutics, meaning drugs and other medical treatments derived from biological …Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ...Adaptive Phage Therapeutics (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. APT’s approach arms us with the unique capability of adapting to the emergence of future antibiotic-resistant superbugs. Our phage bank’s precision targeted ...

Sep 30, 2022 · 2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ... Adaptive Biotechnologies Corporation Registered Shs's market capitalization is $507.61 M by 144.64 M shares outstanding. Adaptive Biotechnologies …

See the latest Adaptive Biotechnologies Corp stock price (ADPT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Jun 30, 2022 · SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ... Apr 12, 2023 · Mark Adams, chief operating officer of Adaptive Biotechnologies Corp. (Nasdaq: ADPT), is moving on from the Seattle-based biotech company. In a Tuesday filing with the Securities and Exchange ... Adaptive Biotechnologies reiterates full year 2022 revenue to be in the range of $185 million to $195 million. Webcast and Conference Call Information. Adaptive Biotechnologies will host a conference call to discuss its first quarter 2022 financial results after market close on Wednesday, May 4, 2022 at 4:30 PM Eastern Time.Adaptive Biotechnologies (NASDAQ: ADPT) $4.31 (6.9%) $0.28 Price as of November 17, 2023, 4:00 p.m. ET Overview Return vs. S&P News & Analysis Financial Health …Today's Open Previous Close Market Cap Today's High Today's Low 52 Week High 52 Week Low Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS FeedsNov 9, 2023 · Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ...

Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine.

WORKDAY ADAPTIVE PLANNING. Username or Email * Password * Remember Username Forgot Password.

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …Dec 3, 2023 · 2009. 790. Chad Robins. https://www.adaptivebiotech.com. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions ... ADPT. 3.50%. Beam Therapeutics Inc. BEAM. 3.48%. View Top Holdings and Key Holding Information for ARK Genomic Revolution ETF (ARKG).Shares of Adaptive Biotechnologies (ADPT-5.20%) soared when the biotech took steps to address the coronavirus pandemic and partnered with Amgen (AMGN 1.14%) and Microsoft (MSFT 0.02%) in the process.Oct 17, 2023 · Adaptive Biotechnologies Corporation Registered Shs's market capitalization is $507.61 M by 144.64 M shares outstanding. Adaptive Biotechnologies Corporation Registered Shs Stock Snapshot 3.30 ADPT. 3.50%. Beam Therapeutics Inc. BEAM. 3.48%. View Top Holdings and Key Holding Information for ARK Genomic Revolution ETF (ARKG).Andrew Brackmann. Adaptive Biotechnologies is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Adaptive Biotechnologies's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Adaptive Biotechnologies or its management.a7ed6ffe1a1f9.jFiJoAHIa3piv51GiAo19GOwUUIqKo36fzhy2FQYhTA.4RHE1VOFJiAS2s4L10hzkgqDC3VwfPSCOFoirTxu40b2Fc-SRoI9NTbarQ Advanced searchGet a real-time Adaptive Biotechnologies Corporation (ADPT) stock price quote with breaking news, financials, statistics, charts and more. ... The 12-month stock ...We publish analysis and forecasts to help you choose the right strategies for trading Adaptive Biotechnologies Corporation stock today, tomorrow and in the ...Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine.

We publish analysis and forecasts to help you choose the right strategies for trading Adaptive Biotechnologies Corporation stock today, tomorrow and in the ...Nkarta’s stock price rose by 112% following its announcement of the FDA clearance, Fierce Biotech reported. Oct. 13: Pfizer late Friday launched a sweeping cost-cutting initiative aimed at generating $3.5 billion in savings through 2024 as the company weathers a steep decline in the sales of its COVID-19 products.Nkarta’s stock price rose by 112% following its announcement of the FDA clearance, Fierce Biotech reported. Oct. 13: Pfizer late Friday launched a sweeping cost-cutting initiative aimed at generating $3.5 billion in savings through 2024 as the company weathers a steep decline in the sales of its COVID-19 products.Instagram:https://instagram. best way to invest 2000 dollarseastman kodak stockvanguard primecap admiralvanguard vgsh London, England, UK Biotech Blogs are designed for people working in the pharmaceutical and biotechnology industries. These blogs include technical articles, articles on ... companies in the industry, information on potential collaborations, and alliances and employment opportunities and also provide commercial, legal, political and scientific …This is an initial public offering of shares of common stock of Adaptive Biotechnologies Corporation. ... Biotech, Inc. (“ALCYONE”), evaluated Darzalex in ... best investment firmsamaazon shopping Nov 9, 2023 · SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ... inexpensive brokerage accounts American Stock Transfer & Trust Company, LLC. AST Shareholder Services Call Center Toll Free: 800.937.5449 Local & International: 718-921-8124 Hours: 8 a.m. – 8 p.m. ET Monday-Friday. American Stock Transfer & Trust Company, LLC 6201 15th Avenue Brooklyn, NY 11219 Email WebsiteAdaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ...The latest closing stock price for Adaptive Biotechnologies as of October 31, 2023 is 4.44. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on January 22, 2021. The Adaptive Biotechnologies 52-week high stock price is 10.79, which is 143% above the current share price. The Adaptive Biotechnologies 52-week low stock ...